Se-Il Go, Sungwoo Park, Myoung Hee Kang, Hoon-Gu Kim, Jung Hun Kang, Jung Hoon Kim, Gyeong-Won Lee
{"title":"内皮细胞激活和应激指数(EASIX)作为小细胞肺癌的预测性生物标志物。","authors":"Se-Il Go, Sungwoo Park, Myoung Hee Kang, Hoon-Gu Kim, Jung Hun Kang, Jung Hoon Kim, Gyeong-Won Lee","doi":"10.3233/CBM-220032","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Endothelial activation and insult may contribute to the aggressive clinical course of small-cell lung cancer (SCLC); however, no predictive biomarker for this pathogenesis has been identified.</p><p><strong>Objective: </strong>To evaluate the clinical impact of the endothelial activation and stress index (EASIX) in SCLC.</p><p><strong>Methods: </strong>In this retrospective study, the EASIX was calculated from measurements of serum lactate dehydrogenase, creatinine, and platelet levels. A total of 264 patients with SCLC treated with platinum-based chemotherapy were stratified into high and low EASIX groups.</p><p><strong>Results: </strong>Complete and objective response rates in the limited-stage (LD) were 19.5% vs. 33.3% (P= 0.050) and 85.4% vs. 97.9% (P= 0.028) in the high and low EASIX groups, respectively. There was no significant difference in the response rate between the two groups in the extensive-stage (ED). The median overall survival was 9.8 vs. 40.5 months in LD (P< 0.001) and 7.2 vs. 11.9 months in ED (P< 0.001) in the high and low EASIX groups, respectively. In multivariate analyses, a high EASIX level was an independent prognostic factor for worse progression-free and overall survival irrespective of stage.</p><p><strong>Conclusion: </strong>EASIX may be a potential predictive biomarker of SCLC.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"217-225"},"PeriodicalIF":1.9000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Endothelial activation and stress index (EASIX) as a predictive biomarker in small cell lung cancer.\",\"authors\":\"Se-Il Go, Sungwoo Park, Myoung Hee Kang, Hoon-Gu Kim, Jung Hun Kang, Jung Hoon Kim, Gyeong-Won Lee\",\"doi\":\"10.3233/CBM-220032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Endothelial activation and insult may contribute to the aggressive clinical course of small-cell lung cancer (SCLC); however, no predictive biomarker for this pathogenesis has been identified.</p><p><strong>Objective: </strong>To evaluate the clinical impact of the endothelial activation and stress index (EASIX) in SCLC.</p><p><strong>Methods: </strong>In this retrospective study, the EASIX was calculated from measurements of serum lactate dehydrogenase, creatinine, and platelet levels. A total of 264 patients with SCLC treated with platinum-based chemotherapy were stratified into high and low EASIX groups.</p><p><strong>Results: </strong>Complete and objective response rates in the limited-stage (LD) were 19.5% vs. 33.3% (P= 0.050) and 85.4% vs. 97.9% (P= 0.028) in the high and low EASIX groups, respectively. There was no significant difference in the response rate between the two groups in the extensive-stage (ED). The median overall survival was 9.8 vs. 40.5 months in LD (P< 0.001) and 7.2 vs. 11.9 months in ED (P< 0.001) in the high and low EASIX groups, respectively. In multivariate analyses, a high EASIX level was an independent prognostic factor for worse progression-free and overall survival irrespective of stage.</p><p><strong>Conclusion: </strong>EASIX may be a potential predictive biomarker of SCLC.</p>\",\"PeriodicalId\":520578,\"journal\":{\"name\":\"Cancer biomarkers : section A of Disease markers\",\"volume\":\" \",\"pages\":\"217-225\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer biomarkers : section A of Disease markers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3233/CBM-220032\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer biomarkers : section A of Disease markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-220032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Endothelial activation and stress index (EASIX) as a predictive biomarker in small cell lung cancer.
Background: Endothelial activation and insult may contribute to the aggressive clinical course of small-cell lung cancer (SCLC); however, no predictive biomarker for this pathogenesis has been identified.
Objective: To evaluate the clinical impact of the endothelial activation and stress index (EASIX) in SCLC.
Methods: In this retrospective study, the EASIX was calculated from measurements of serum lactate dehydrogenase, creatinine, and platelet levels. A total of 264 patients with SCLC treated with platinum-based chemotherapy were stratified into high and low EASIX groups.
Results: Complete and objective response rates in the limited-stage (LD) were 19.5% vs. 33.3% (P= 0.050) and 85.4% vs. 97.9% (P= 0.028) in the high and low EASIX groups, respectively. There was no significant difference in the response rate between the two groups in the extensive-stage (ED). The median overall survival was 9.8 vs. 40.5 months in LD (P< 0.001) and 7.2 vs. 11.9 months in ED (P< 0.001) in the high and low EASIX groups, respectively. In multivariate analyses, a high EASIX level was an independent prognostic factor for worse progression-free and overall survival irrespective of stage.
Conclusion: EASIX may be a potential predictive biomarker of SCLC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
